Company Directory

Silica encapsulation platform eliminating cold chain for biologics

EnsiliTech is a biotechnology company developing ensilication, a patented platform technology that encases vaccines, antibodies, and other biologics within a silica matrix to render them thermally stable without refrigeration. The technology is applicable to existing and new biopharmaceutical formulations, enabling storage and transport at temperatures up to 50°C. EnsiliTech is developing applications across vaccines and monoclonal antibody therapeutics, with partners including the Centre for Process Innovation.

Surface acoustic wave nebuliser platform for inhaled drug delivery

Nebu~Flow is a UK medical technology company developing next-generation nebuliser devices using patented surface acoustic wave technology to aerosolise drugs into precisely controlled droplet sizes for deep lung deposition. The platform is designed to enable inhalation delivery of biologics, RNA-based formulations, and other hard-to-nebulise drugs that currently lack viable pulmonary delivery routes. The company works with pharmaceutical partners to validate the technology ahead of regulatory submission.

Preventing cancer therapy side effects with topical medicines

VasoDynamics is a clinical-stage pharmaceutical development company focused on preventing the debilitating side effects of cancer therapy. The company develops topical formulations targeting radiation-induced oral mucositis, dermatitis, and chemotherapy-induced hair loss, using vasoconstrictor and radioprotective compounds. Its technology platform, based on IP licensed from leading UK and US research institutions, has progressed through Phase Ib and Phase IIa clinical trials. VasoDynamics serves oncology patients undergoing radiotherapy and chemotherapy.

Oral and injectable peptide therapies for obesity and cardiometabolic disease

Verdiva Bio is a clinical-stage biopharmaceutical company developing next-generation oral and injectable treatments for obesity and cardiometabolic disorders. Its pipeline centres on rationally engineered peptide candidates acting on GLP-1 and amylin receptors, advanced through a proprietary oral absorption technology designed to enable once-weekly dosing. The lead programme is in Phase 2b clinical development, with earlier-stage amylin candidates in preclinical development for monotherapy and combination use.

Pharmaceutical formulation development and clinical manufacturing services

SGS Quay Pharma is a contract development and manufacturing organisation providing formulation development, analytical services, and clinical trial manufacturing for pharmaceutical and biotechnology companies. The company specialises in dosage form design for APIs with challenging solubility and bioavailability profiles, and in modified and controlled release formulations. Operating from a MHRA and FDA-approved facility in North Wales, it supports clients from preclinical stage through to Phase III and commercial manufacture.

Specialist CRO for inhaled and nasal drug product development

Nanopharm is a contract research organisation specialising in the development of orally inhaled and nasal drug products, providing formulation development, materials characterisation, analytical testing, and in vitro and in silico modelling services to pharmaceutical and biotechnology clients. The company supports development from preclinical through to cGMP clinical stages, including regulatory strategy. Its proprietary platform enables bioequivalence demonstration for generic inhalation products without comparative clinical endpoint studies.

Engineered immune cells as living delivery vehicles for genetic medicines

Dart Biosciences is a biotechnology company developing a platform that uses engineered immune cells as living delivery vehicles for genetic medicines. By leveraging immune cells' natural ability to localise to disease-relevant tissues, the platform aims to achieve more spatially precise genetic payload transfer with reduced systemic exposure compared to viral vectors and lipid nanoparticles. The modular architecture is designed to support conditional payload release and repeat administration across multiple disease areas.

Xeno nucleic acid binders for targeted drug delivery

Xterna is a biotechnology company developing cell-specific molecular binders composed of xeno nucleic acids (XNAs), chemically modified nucleic acids distinct from naturally occurring DNA and RNA. XNA-based binders are engineered to target cell types that evade conventional antibody-based approaches, enabling drug delivery to previously inaccessible tissues. The platform is designed to carry nucleic acid therapeutic payloads, improving delivery precision and reducing off-target effects.

Plant protein materials replacing plastics and microplastics

Xampla is a Cambridge-based materials innovation company developing plant protein-based alternatives to single-use plastics and synthetic microplastics. Its range of products includes biodegradable coatings, soluble films, edible films, and microcapsules derived from sustainable vegetable proteins such as pea, rapeseed and sunflower. Applications span food and beverage packaging, homecare, personal care, and active ingredient encapsulation. Xampla's technology, rooted in protein self-assembly research, is the basis of partnerships with major FMCG and packaging brands globally.

Microgravity-based CDMO platform for crystallisation of biologic drugs

BioOrbit is a biotech developing a proprietary hardware platform for the crystallisation of protein-based biologic drugs in low Earth orbit. The company exploits the absence of gravity-driven convection in microgravity to produce larger, more uniform protein crystals than ground-based methods allow, enabling high-concentration, low-viscosity formulations suitable for subcutaneous delivery. It is targeting monoclonal antibodies as its primary application, with its first orbital payload delivered in 2024.

Viral vector platform for solid tumour immunotherapy

Akamis Bio is a clinical-stage oncology company developing oncolytic adenoviral therapeutics for solid tumours. Its platform delivers immunotherapeutic payloads directly to tumour sites following intravenous dosing, enabling tumour-localised expression of proteins including CD40 agonist antibodies and cytokines. Lead programme NG-350A is in a Phase 1b trial for locally advanced rectal cancer, having received FDA Fast Track Designation; NG-641 is in Phase 1 combination studies in advanced epithelial tumours.

Lyophilisation equipment, CDMO services, and freeze-drying expertise

Biopharma Group is a contract development and manufacturing organisation and capital equipment supplier specialising in lyophilisation and liquid formulation technologies. The company serves pharmaceutical, biotechnology, and diagnostics clients across two divisions: an equipment sales and technical service division supplying freeze dryers, aseptic fill-finish lines, and cryogenic storage systems; and a CDMO division providing formulation development, cycle development, and GMP and non-GMP contract manufacturing.